<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212022000400311</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2022.12.095</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Dupilumab: para além da dermatite atópica]]></article-title>
<article-title xml:lang="en"><![CDATA[Dupilumab beyond atopic dermatitis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[Rita Queiroz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[Carmo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Rui]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE Serviço de Pneumologia ]]></institution>
<addr-line><![CDATA[Vila Real ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro Hospitalar do Baixo Vouga, EPE Serviço de Imunoalergologia ]]></institution>
<addr-line><![CDATA[Estarreja Portugal]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE Serviço de Imunoalergologia ]]></institution>
<addr-line><![CDATA[Vila Real ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>30</volume>
<numero>4</numero>
<fpage>311</fpage>
<lpage>317</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212022000400311&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212022000400311&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212022000400311&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A dermatite atópica pode estar associada à alergia alimentar e outras doenças atópicas. Relatamos o caso clínico de adolescente, sexo feminino, com rinoconjuntivite e asma grave alérgicas, referenciada para estudo de dermatite atópica, que apresentava lesões cutâneas apenas parcialmente responsivas a corticoterapia sistémica e fototerapia, com várias exacerbações e uma hospitalização. História de exacerbação das lesões cutâneas, náuseas e vómitos com a ingestão de ovos inteiros, leite e marisco. Foram realizados testes cutâneos por picada e IgE específicas, bem como teste ImmunoCAP®-ISAC, que mostraram polissensibilização a aeroalergénios e alergénios alimentares. Espirometria com síndrome obstrutiva moderadamente grave. Devido à gravidade do eczema, iniciou-se tratamento com dupilumab, com melhoria acentuada das lesões cutâneas logo após 2 semanas; aos 5 meses, reintrodução do ovo na dieta; aos 7 meses, normalização da espirometria. Este caso suporta a eficácia do dupilumab no tratamento da dermatite atópica, asma grave e aquisição de tolerância na alergia alimentar, esta ainda com opções terapêuticas limitadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Severe forms of atopic dermatitis can be associated with food allergy and other atopic diseases. We report the clinical case of a female teenager with allergic rhinoconjunctivitis and severe asthma, referred for evaluation of atopic dermatitis, that presented skin lesions only partially responsive to systemic corticosteroids and phototherapy, with multiple exacerbations and hospitalization. Exacerbation of skin lesions, nausea and vomiting on eating eggs, milk and shellfish. Skin prick test, specific IgE and ImmunoCAP®-ISAC test were performed, showing polysensitization to aeroallergens and food allergens. The spirometry showed moderately severe obstructive syndrome. Due to the eczema severity, dupilumab was started with marked improvement of skin lesions after only two weeks; at five months, she reintroduced egg into the diet; at seven months, the spirometry was normal. This case supports the effectiveness of dupilumab in treating atopic dermatitis, severe asthma and the acquisition of tolerance to food allergy, the latter with still limited therapeutic options.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Alergia alimentar]]></kwd>
<kwd lng="pt"><![CDATA[asma]]></kwd>
<kwd lng="pt"><![CDATA[dermatite atópica]]></kwd>
<kwd lng="pt"><![CDATA[dupilumab]]></kwd>
<kwd lng="en"><![CDATA[Asthma]]></kwd>
<kwd lng="en"><![CDATA[atopic dermatitis]]></kwd>
<kwd lng="en"><![CDATA[dupilumab]]></kwd>
<kwd lng="en"><![CDATA[food allergy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weston]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Howe]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Post]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
</person-group>
<source><![CDATA[UpToDate]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aït-Khaled]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Anabwani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>1999</year>
<volume>103</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>125-38</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[KF]]></given-names>
</name>
<name>
<surname><![CDATA[Wenzel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Brozek]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sterk]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>343-73</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerkhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Golam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hillyer]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population]]></article-title>
<source><![CDATA[Thorax]]></source>
<year>2018</year>
<volume>73</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>116-24</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Pirozzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[NMH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Commonality of the IL-4/ IL-13 pathway in atopic diseases]]></article-title>
<source><![CDATA[Expert Rev Clin Immunol]]></source>
<year>2017</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>425-37</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gandhi]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Bennett]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[NMH]]></given-names>
</name>
<name>
<surname><![CDATA[Pirozzi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yancopoulos]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting key proximal drivers of type 2 inflammation in disease]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2016</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Spergel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The atopic march: Critical evidence and clinical relevance]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2018</year>
<volume>120</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gianni]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Auricchio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brunetti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mancino]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atopic dermatitis and asthma]]></article-title>
<source><![CDATA[Allergy Asthma Proc]]></source>
<year>2007</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>540-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaffin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Sheehan]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Morrill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cinar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Borras Coughlin]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Sawicki]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tree nut allergy, egg allergy, and asthma in children]]></article-title>
<source><![CDATA[Clin Pediatr]]></source>
<year>2011</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relatório público de avaliação prévia do medicamento em meio hospitalar - dupilumab]]></article-title>
<source><![CDATA[Infarmed]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dupixent, dupilumab - summary of product characteristics]]></article-title>
<source><![CDATA[European Medicines Agency]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Paller]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Siegfried]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Boguniewicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sher]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gooderham]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of dupilumab in adolescentes with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Dermatol]]></source>
<year>2020</year>
<volume>156</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-56</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dupilumab and milk OIT for the treatment of cow&#8217;s milk allergy]]></article-title>
<source><![CDATA[National Library of Medicine]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Effectiveness of dupilumab in food allergic patients with moderate to severe atopic dermatitis]]></article-title>
<source><![CDATA[National Library of Medicine]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rial]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sastre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupilumab for treatment of food allergy]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2019</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>673-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bawany]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dupilumab: One therapy to treat multiple atopic diseases]]></article-title>
<source><![CDATA[JAAD Case Rep]]></source>
<year>2020</year>
<volume>6</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1150-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
